Early increase of CD103 expression on peripheral PD-1+ CD8+ T cells predicts response to nivolumab in advanced esophageal squamous cell carcinoma

Abstract Background Nivolumab has become a standard treatment for advanced or recurrent esophageal squamous cell carcinoma (ESCC). However, reliable blood-based biomarkers predictive of response remain undefined. We investigated dynamic changes in peripheral PD-1+ CD8+ T-cell subsets during nivoluma...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Satoko Sumimoto, Tomoki Makino, Shigeto Nakai, Takaomi Hagi, Kota Momose, Kotaro Yamashita, Takuro Saito, Koji Tanaka, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Springer 2026-05-01
Edice:	Cancer Immunology, Immunotherapy
Témata:	Esophageal cancer CD103 Nivolumab T-cell
On-line přístup:	https://doi.org/10.1007/s00262-026-04429-5
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!